Second Annual
R&D
Strategies:
Managing Risk to Increase R&D
Productivity
May 17-18,
2004
Philadelphia,
PA
Register Today
Download Brochure
Plenary
Keynotes:
Robert R.
Ruffolo, Ph.D.,
President, Research & Development,
Wyeth
Pharmaceuticals;
Senior Vice President,
Wyeth
Corporation
Jan-Anders
Karlsson, Ph.D.
Executive Vice President,
Pharma Research,
Bayer Healthcare AG
Gianni Gromo
M.D.,
Head of Discovery Research
Basel, F. Hoffmann-La Roche
Ltd.
Topics to
be Covered:
-
Creating an R&D Model That
Best Positions -
Your Organization to Increase
Profitability -
Implementing Strategies to Improve
-
Quality of Your Validated Targets
-
Going Beyond Scenario-Based
Planning into Predictive Mode -
Profiting from Discovery and
Marketing Collaboration -
Increasing an Individual Scientist's
Productivity
Corporate Sponsors:
Lead
Sponsoring
Publications:
R&D Strategies
is One of the Five Conferences
at CHI's The
World Pharmaceutical Congress- ID3
The
Other Four Parts of The Congress
are:
ADME/Tox: From A to
T
Cheminformatics: Data Driving
Decisions
Cell-based Assays for HTS
Hit-to-Lead:Streamlining Lead
Generation
SPECIAL FDA
PRESENTATION
Orphan Drug Designation to Encourage Innovation
Bradley Glasscock, Pharm.D., Office
of Orphan Products Development,
Food & Drug
Administration
Strategic View of Risk
Assessment
R&D Productivity Enhancement Through Focus on Drugable
Targets:
How to Differentiate
?
Daniel Schirlin,
Ph.D., Head of Global Lead Generation,
Aventis
The Future of Research
Productivity and Innovation
Mark Seidler, Ph.D., Senior Engagement Manager,
Strategic Decisions Group
Strategy, Portfolio
Management &
Risk
Integrated Approach to Portfolio Management: Linking
Discovery to
the Market through Clinical
Development
Rick
Bayney, Ph.D., Vice President, Portfolio Management, PRD,
Johnson & Johnson
Integrated
R&D/Commercial Cross-Functional Approaches
to
Strategy, Portfolio and Risk
Ramana Sonty, Senior
Director/Team Leader, World Wide
Development, Pfizer Global
Pharmaceuticals
R&D Strategy and
Knowledge
Management
Implementing
Strategies to Improve the Quality of
Your Validated
Targets
Douglas Axelrod, Ph.D., R&D Manager, Discovery and
Early
Development, Proctor &
Gamble
Improving
collaboration and decision making through
Knowledge
Management
Harvey L. Wiener, Ph.D., M.B.A., Associate Director,
Knowledge Integration Resources, Bristol-Myers Squibb Company
Managing Knowledge for the Business of
Science
Joseph A. Cerro, Head of Informatics Research,
Bayer
Pharmaceuticals Corporation
Interactive Panel
|
Innovator or Fast Follower?
Creating a Model that Best Panelists:
|
Creating A Productive R&D
Organization
The Unconventional Mindset: A Case
Study in Mitigating
R&D 'Decision
Risk'
Thomas Unger, Ph.D., Vice President - Life Sciences, Wood
Mackenzie
Kevin Koch, Ph.D., President and Chief Scientific Officer, Array BioPharma
Creating Drug Hunters: Increasing an Individual Scientist's Productivity
Andrew Hopkins, Ph.D., Senior Principal Scientist, Molecular Informatics,
Pfizer Global Research and Development
R&D Fiscal Responsibility
A Challenging Strategy: Going Beyond Scenario-based Planning
into Predictive Mode
James Resch, Ph.D., Director, Strategic Planning, Drug Discovery,
AstraZeneca
Profiting from Discovery and Marketing Collaboration
Matthew Bell, Ph.D., Director, Discovery Research Strategy,
Wyeth Pharmaceuticals
Evaluating Outsourcing Options in Drug Discovery - Balancing R&D
Opportunities with External Partnerships
Ron Newbold, Ph.D., Senior Director, Strategic Research Initiatives,
External Scientific Affairs, Merck & Co For More Information on this Event Visit:
www.chi-intelligentdrug.com